Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk Factors for Steroid-Refractory Acute Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation from Matched Related or Unrelated Donors.
Calmettes C, Vigouroux S, Labopin M, Tabrizi R, Turlure P, Lafarge X, Marit G, Pigneux A, Leguay T, Bouabdallah K, Dilhuydy MS, Duclos C, Mohr C, Lascaux A, Dumas PY, Dimicoli-Salazar S, Saint-Lézer A, Milpied N. Calmettes C, et al. Among authors: lafarge x. Biol Blood Marrow Transplant. 2015 May;21(5):860-5. doi: 10.1016/j.bbmt.2015.01.016. Epub 2015 Jan 21. Biol Blood Marrow Transplant. 2015. PMID: 25617807 Free article.
Methotrexate Reduces the Incidence of Severe Acute Graft-versus-Host Disease without Increasing the Risk of Relapse after Reduced-Intensity Allogeneic Stem Cell Transplantation from Unrelated Donors.
Vigouroux S, Tabrizi R, Melot C, Coiffard J, Lafarge X, Marit G, Bouabdallah K, Pigneux A, Leguay T, Dilhuydy MS, Schmitt A, Boiron JM, Milpied N. Vigouroux S, et al. Among authors: lafarge x. Biol Blood Marrow Transplant. 2011 Jan;17(1):93-100. doi: 10.1016/j.bbmt.2010.06.013. Epub 2010 Jun 19. Biol Blood Marrow Transplant. 2011. PMID: 20601038 Free article.
Potent graft-versus-leukemia effect after reduced-intensity allogeneic SCT for intermediate-risk AML with FLT3-ITD or wild-type NPM1 and CEBPA without FLT3-ITD.
Labouré G, Dulucq S, Labopin M, Tabrizi R, Guérin E, Pigneux A, Lafarge X, Leguay T, Bouabdallah K, Dilhuydy MS, Duclos C, Lascaux A, Marit G, Mahon FX, Boiron JM, Milpied N, Vigouroux S. Labouré G, et al. Among authors: lafarge x. Biol Blood Marrow Transplant. 2012 Dec;18(12):1845-50. doi: 10.1016/j.bbmt.2012.06.012. Epub 2012 Jul 2. Biol Blood Marrow Transplant. 2012. PMID: 22766221 Free article.
Comparable outcome after related or unrelated allogeneic stem cell transplant following reduced conditioning with fludarabine, busulfan and antithymocyte globulin.
Vigouroux S, Tabrizi R, Melot C, Coiffard J, Lafarge X, Marit G, Bouabdallah K, Pigneux A, Leguay T, Dilhuydy MS, Schmitt A, Boiron JM, Milpied N. Vigouroux S, et al. Among authors: lafarge x. Leuk Lymphoma. 2012 Jan;53(1):162-5. doi: 10.3109/10428194.2011.604754. Epub 2011 Aug 18. Leuk Lymphoma. 2012. PMID: 21756024 No abstract available.
Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD.
Carapito R, Jung N, Kwemou M, Untrau M, Michel S, Pichot A, Giacometti G, Macquin C, Ilias W, Morlon A, Kotova I, Apostolova P, Schmitt-Graeff A, Cesbron A, Gagne K, Oudshoorn M, van der Holt B, Labalette M, Spierings E, Picard C, Loiseau P, Tamouza R, Toubert A, Parissiadis A, Dubois V, Lafarge X, Maumy-Bertrand M, Bertrand F, Vago L, Ciceri F, Paillard C, Querol S, Sierra J, Fleischhauer K, Nagler A, Labopin M, Inoko H, von dem Borne PA, Kuball J, Ota M, Katsuyama Y, Michallet M, Lioure B, Peffault de Latour R, Blaise D, Cornelissen JJ, Yakoub-Agha I, Claas F, Moreau P, Milpied N, Charron D, Mohty M, Zeiser R, Socié G, Bahram S. Carapito R, et al. Among authors: lafarge x. Blood. 2016 Oct 13;128(15):1979-1986. doi: 10.1182/blood-2016-05-719070. Epub 2016 Aug 22. Blood. 2016. PMID: 27549307 Free PMC article. Clinical Trial.
Is there any impact of HLA-DPB1 disparity in 10/10 HLA-matched unrelated hematopoietic SCT? Results of a French multicentric retrospective study.
Gagne K, Loiseau P, Dubois V, Dufossé F, Perrier P, Dormoy A, Jollet I, Renac V, Masson D, Picard C, Lafarge X, Hanau D, Quainon F, Delbos F, Coeffic B, Absi L, Eliaou JF, Moalic V, Fort M, de Matteis M, Theodorou I, Hau F, Batho A, Pedron B, Caillat-Zucman S, Marry E, Raus N, Yakoub-Agha I, Cesbron A. Gagne K, et al. Among authors: lafarge x. Bone Marrow Transplant. 2015 Feb;50(2):232-6. doi: 10.1038/bmt.2014.253. Epub 2014 Nov 3. Bone Marrow Transplant. 2015. PMID: 25365066 Clinical Trial.
Killer immunoglobulin-like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment-free remission.
Dumas PY, Bérard E, Bréal C, Dulucq S, Réa D, Nicolini F, Forcade E, Dufossée M, Pasquet JM, Turcq B, Bidet A, Milpied N, Déchanet-Merville J, Lafarge X, Etienne G, Mahon FX; French Intergroup in Chronic Myeloid Leukemia. Dumas PY, et al. Among authors: lafarge x. Cancer Med. 2019 Sep;8(11):4976-4985. doi: 10.1002/cam4.2371. Epub 2019 Jul 9. Cancer Med. 2019. PMID: 31287239 Free PMC article.
Impact of KIR/HLA genetic combinations on double umbilical cord blood transplantation outcomes. Results of a French multicentric retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) and the Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI).
Rettman P, Malard F, Legrand N, Avinens O, Eliaou JF, Picard C, Dormoy A, Lafarge X, de Matteis M, Kennel A, Loiseau P, Devys A, Boudifa A, Absi L, Fort M, Masson D, Quainon F, Theodorou I, Batho A, Parissiadis A, Delbos F, Drouet M, Senitzer D, Marry E, Raus N, Yakoub-Agha I, Cesbron A, Retière C, Gagne K. Rettman P, et al. Among authors: lafarge x. Bone Marrow Transplant. 2016 Nov;51(11):1499-1503. doi: 10.1038/bmt.2016.151. Epub 2016 Jun 6. Bone Marrow Transplant. 2016. PMID: 27272444 No abstract available.
49 results